Wed, July 20, 2011
[ Wed, Jul 20th 2011 ]: Market Wire
Pfizer To Acquire Icagen
[ Wed, Jul 20th 2011 ]: Market Wire
00 a.m. EDT
Tue, July 19, 2011
Mon, July 18, 2011
[ Mon, Jul 18th 2011 ]: Market Wire
Aetna to Acquire PayFlex
Fri, July 15, 2011
Thu, July 14, 2011
Wed, July 13, 2011
Tue, July 12, 2011
Mon, July 11, 2011
Sun, July 10, 2011
Sat, July 9, 2011
Fri, July 8, 2011
Thu, July 7, 2011
Wed, July 6, 2011
Tue, July 5, 2011
Mon, July 4, 2011
Sat, July 2, 2011
Fri, July 1, 2011
Thu, June 30, 2011
[ Thu, Jun 30th 2011 ]: Market Wire
KCI???NPWT????????????
Wed, June 29, 2011
Tue, June 28, 2011
Mon, June 27, 2011
Sat, June 25, 2011
Fri, June 24, 2011

Medtronic To Acquire Salient Surgical Technologies, Inc.

  Copy link into your clipboard //health-fitness.news-articles.net/content/2011/ .. o-acquire-salient-surgical-technologies-inc.html
  Print publication without navigation Published in Health and Fitness on by Market Wire
          🞛 This publication is a summary or evaluation of another publication

MINNEAPOLIS--([ BUSINESS WIRE ])--Medtronic, Inc. (NYSE: MDT) today announced that it has entered into a definitive agreement to acquire Salient Surgical Technologies, Inc., the leader in the advanced energy category for haemostatic sealing of soft tissue and bone in a variety of surgical procedures includingorthopaedic surgery, spine,open abdominal and thoracic procedures. Salienta™s AQUAMANTYS® system with patented TRANSCOLLATION® technology will broaden Medtronic Surgical Technologiesa™ portfolio of innovative surgical products to meet customer and patient needs worldwide.

"Integrating the Salient Surgical Technologies organization will bring new applications to Medtronic Surgical Technologiesa™ current surgical therapy areas and expand the companya™s opportunities in adjacent offerings, helping Medtronic serve new customers and better meet the needs of existing ones"

The total value of the transaction is $525 million. Medtronic had previously invested in Salient and currently holds an ownership stake in the company. Net of this ownership stake, the transaction value is approximately $480 million. Salient's revenue is annualizing at approximately $100 million and is growing rapidly.

Salient Surgical Technologiesa™ rapidly expanding advanced energy product lines provide a strong value proposition to patients, surgeons, and hospitals through haemostatic sealing of soft tissue and bone, reduced blood loss and improved surgeon visualization.

The companya™s patented TRANSCOLLATION® technology has enabled healthcare professionals to optimize care for more than 650,000 patients worldwide undergoing a variety of surgical procedures includingorthopaedic surgery, spine,open abdominal and thoracic procedures.

aIntegrating the Salient Surgical Technologies organization will bring new applications to Medtronic Surgical Technologiesa™ current surgical therapy areas and expand the companya™s opportunities in adjacent offerings, helping Medtronic serve new customers and better meet the needs of existing ones,a said Chris Oa™Connell, executive vice president and president of Medtronica™s Restorative Therapies Group.

Joseph Army, president and CEO of Salient Surgical Technologies, said, aSalienta™s focus on improving patient outcomes and its commitment to having the best people in the medical device industry align perfectly with Medtronica™s mission and culture. We are excited about the opportunity to become part of the global leader in medical technology and look forward to leveraging Medtronica™s worldwide presence to make TRANSCOLLATION® technology the standard of care in advanced energy across the globe.a

In a separate development today, Medtronic announced it has signed an agreement to acquire PEAK Surgical, Inc. another leader in advanced energy surgical technology, particularly in the area of advanced incision products. Together, these acquisitions represent Medtronica™s commitment to innovation across the entire surgical continuum from incision to closing, and represent entries into new areas such as plastic/reconstruction, electrophysiology, oncology and large bone orthopedics.

The acquisition is subject to governmental and regulatory review in the U.S. and several countries. Until the transaction is cleared and closed, the companies will continue to operate as separate entities.

About Salient Surgical Technologies
Salient Surgical Technologies, Inc. ([ www.salientsurgical.com ]) is a medical technology company that develops and markets advanced energy devices for use in surgical procedures. The companya™s AQUAMANTYS® System uses patented TRANSCOLLATION® technology, which provides hemostatic sealing of soft tissue and bone tissue at the surgical site. This technology has been used to optimize care for more than 650,000 patients undergoing a variety of surgical procedures includingorthopaedic surgery, spine,open abdominal and thoracic procedures.

About Medtronic
Medtronic, Inc. ([ www.medtronic.com ]), headquartered in Minneapolis, is the global leader in medical technology a" alleviating pain, restoring health and extending life for millions of people around the world.

Safe Harbor
This Press Release contains forward-looking statements that may include statements regarding the intent, belief or current expectations ofSalient Surgical Technologies, Medtronic and their respective management. Forward looking statements include statements about the benefits and advantages of the acquisition forSalient Surgical and Medtronic. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of important factors, including but not limited to the risk that the acquisition will not close as the transaction is subject to certain closing conditions, such as the ability to obtain regulatory approvals of the proposed acquisition. In addition, if and when the transaction is closed, there will be risks and uncertainties related to Medtronica™s ability to integrateSalient Surgical Technologies successfully, the risk that the cost savings and any other synergies from the acquisition may not be fully realized or may take longer to realize than expected; disruption from the acquisition making it more difficult to maintain relationships with customers, employees or suppliers; and competition and its effect on pricing, spending, third-party relationships and revenues. Additional factors that may affect future results are contained in the SEC filings for Medtronic, including but not limited to Medtronica™s Annual Report on Form 10-K for the year ended April 29, 2011. Medtronic andSalient Surgical Technologies each disclaim any obligation to update and revise statements contained in this release based on new information or otherwise.